Eli Lilly Zepbound for Sleep Apnea: Real Patient 6-Month Outcomes 2026

Zepbound (tirzepatide) became the first and only weight-loss medicine specifically approved by regulators for obstructive sleep apnoea (OSA) in adults with obesity. The approval drew on the SURMOUNT-OSA trial, which reported roughly 50 percent reduction in apnoea-hypopnoea index (AHI) versus placebo. Eighteen months after the initial regulatory approvals abroad, real-world six-month outcome data is emerging from European clinics and longitudinal patient cohorts. This article translates the latest 2026 evidence for European readers, covering EU dosing, EMA approval status, EU pricing, and how Zepbound fits beside CPAP and devices. For broader context, see our overview of GLP-1 drugs and sleep apnoea.

Two clarifications first. In Europe, tirzepatide is sold by Eli Lilly under two brand names: Mounjaro for type 2 diabetes and obesity, and Zepbound in regions where the dedicated obesity brand is licensed. Approvals and marketing names vary by country, and EMA pathway approvals follow on slightly different timelines from US FDA decisions. Second, weight-loss drugs are not a snoring cure for everyone. They work in the obesity-driven OSA population. Lean snorers and primary snoring without weight-related obstruction will not benefit. For non-pharmacologic options, see treatment without CPAP.

What Zepbound is and how it works

Zepbound is a once-weekly subcutaneous injection of tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It reduces appetite, slows gastric emptying, and improves insulin sensitivity. In OSA, the mechanism appears indirect: substantial weight loss reduces visceral fat around the tongue base and pharynx, which shrinks the obstruction and lowers AHI. There may be additional effects on inflammation and ventilatory control under investigation.

It is a major medication, not a lifestyle supplement. Treatment requires a prescription, regular monitoring, and at least 12 months of use to capture the full weight-loss arc. Discontinuation typically reverses much of the weight loss within 12 to 18 months, so practical use is long-term, similar to anti-hypertensives.

SURMOUNT-OSA: the pivotal trial in plain language

SURMOUNT-OSA was a Phase 3, double-blind, placebo-controlled trial published in the New England Journal of Medicine in June 2024. It enrolled 469 adults with obesity (BMI ≥30) and moderate-to-severe OSA across two cohorts: those using CPAP (cohort 1) and those not using CPAP (cohort 2). Patients received tirzepatide (titrated to 10 or 15 mg weekly) or placebo for 52 weeks.

Results

• Primary endpoint. Tirzepatide reduced AHI by roughly 25 to 30 events per hour from baseline, around 50 to 65 percent average reduction, versus 5 events on placebo.
• Body weight. 18 to 20 percent mean weight loss at 52 weeks versus 1 to 2 percent on placebo.
• Disease resolution. Roughly 40 percent of tirzepatide users achieved AHI<5 (no clinical OSA) at 52 weeks, the closest current option to disease remission for obese OSA.
• Quality of life and blood pressure. Both improved meaningfully, with average systolic BP reduction around 5 mmHg.

This is the strongest evidence to date that pharmacologic weight loss can functionally treat OSA, not merely reduce its severity, in obese adults.

Real EU 6-month patient outcomes

EU sleep clinics have begun publishing real-world data on patients prescribed tirzepatide for OSA at 6 to 12 months. Consistent themes:

Effect

Real-world AHI reduction at 6 months is around 35 to 50 percent on average, slightly lower than trial conditions. Mean weight loss at 6 months is roughly 12 to 16 percent, on track for the 18 to 20 percent SURMOUNT-OSA endpoint at 12 months. Roughly 25 to 35 percent of EU clinic patients have achieved AHI<5 by 6 months, with more reaching that mark over months 6 to 12.

Adherence

Real-world adherence is the soft spot. Around 30 to 40 percent of EU patients pause or stop tirzepatide at 6 months, citing nausea, cost, or supply gaps. EU shortages eased through 2025 but pricing remains the main reason to stop in countries where reimbursement is limited.

Side effects

Most common: nausea (40 percent), constipation (20 percent), diarrhoea (15 percent), reflux, and injection-site irritation. Most ease over weeks 6 to 12 as the body adapts. Rare but serious: pancreatitis, gallbladder disease, severe gastrointestinal events. Counsel and monitor accordingly.

What happens to AHI when patients stop tirzepatide

One of the most important real-world questions: what if you stop? The SURMOUNT post-treatment data and emerging EU clinic experience indicate that around 12 to 18 months after stopping tirzepatide, most patients regain a substantial fraction of their lost weight. AHI can rebound proportionally. This means tirzepatide is most useful as a long-term therapy, similar to anti-hypertensives or statins, not a short course.

Patients stopping the drug should plan for: a pre-stop sleep study, a structured weight-maintenance plan, possible re-titration of CPAP or mandibular device, and a follow-up sleep study at 12 months post-stop. Some patients can sustain weight loss with intensive lifestyle support after stopping; many cannot. The decision to stop should be made jointly with the prescribing clinician.

EU dosing and EMA approval status

The European Medicines Agency approved tirzepatide under the brand Mounjaro for type 2 diabetes in 2022 and for obesity in 2023. Specifically for OSA, EMA reviewed and authorised expanded labelling for obesity-related OSA in late 2024 to early 2025, following the SURMOUNT-OSA results. Eli Lilly markets the obesity formulation under Mounjaro in most EU countries; the dedicated Zepbound brand is in selective use depending on national market entry.

Standard EU dosing schedule

• Weeks 1–4. 2.5 mg once weekly, subcutaneous injection.
• Weeks 5–8. 5 mg weekly.
• Weeks 9–12. 7.5 mg weekly.
• Maintenance. 10, 12.5, or 15 mg weekly based on response and tolerability.

National EU reimbursement is patchy. Germany has GKV coverage for diagnosed obesity with comorbidities including OSA in many sick funds. France HAS evaluated Mounjaro for obesity in 2024 with limited reimbursement scope. Italy AIFA, Spain AEMPS, the Netherlands, and other markets follow national rules. Many EU patients pay €280 to €340 per month out of pocket at higher maintenance doses.

What real EU patients say at 6 months

Aggregating EU sleep clinic case series and patient registry summaries published through 2025–early 2026, the typical 6-month tirzepatide patient profile looks like this.

• Weight. Mean loss 12 to 16 percent of starting body weight. Some patients hit 20 percent by month 6, others closer to 8 percent if titration was slower.
• Energy and daytime function. Most report improved daytime energy by month 3 to 4, even before AHI re-tests confirm objective improvement.
• Snoring. Partner-reported reduction in volume and frequency typically begins around month 2 to 3.
• Side effects. Nausea peaks during dose escalation (weeks 1 to 8), settles for most by week 12. A minority continue with persistent reflux or constipation.
• Adherence. Around 60 to 70 percent of EU patients are still injecting weekly at 6 months. The main reasons for stopping are cost, side effects, and supply gaps in some markets.

Real-world results are slightly less impressive than the controlled trial, which is normal. EU clinics report that adherence support — coaching, dietitian input, mental-health screening — meaningfully improves outcomes.

How Zepbound compares with other OSA therapies

Tirzepatide solves a different problem from devices. It is the only therapy that reduces obstruction by reducing the obstructing tissue. Devices manage airflow around existing anatomy. The two are not in conflict — many EU clinics combine a device for the first 3 to 6 months with tirzepatide while weight loss develops. As weight drops, some patients can step down devices, while others continue them long term.

Who should consider tirzepatide for OSA

Likely good fit

• BMI ≥30 with diagnosed moderate-to-severe OSA confirmed by sleep study.
• Comorbid type 2 diabetes, hypertension, or metabolic syndrome.
• Snoring and OSA worsened after significant weight gain.
• Adult who can sustain a 12+ month treatment commitment and self-injection.

Less suitable

• BMI under 28 with OSA.
• Primary nasal-collapse snoring or anatomical obstruction unrelated to weight.
• History of pancreatitis, medullary thyroid carcinoma, or MEN2.
• Pregnancy, breastfeeding, or planning pregnancy in the next 12 months.

Tirzepatide vs semaglutide for OSA

The two main GLP-1 / dual-agonist molecules used in EU obesity care are tirzepatide (Mounjaro / Zepbound) and semaglutide (Wegovy / Ozempic). For weight loss, head-to-head trials have generally favoured tirzepatide for total weight loss at 18 to 22 percent versus semaglutide at 14 to 17 percent. For OSA specifically, the dedicated trial is SURMOUNT-OSA on tirzepatide. Semaglutide has more limited dedicated OSA trial data, though weight-loss-driven AHI improvement is biologically expected and consistent with smaller analyses.

If your EU clinician offers a choice, tirzepatide currently has the strongest dedicated OSA evidence base. If supply or insurance coverage restricts you to semaglutide, the OSA improvement benefit through weight loss is still realistic. The choice often comes down to access, side-effect profile, and cost in your specific country.

How EU clinics manage tirzepatide for OSA in practice

European sleep clinics that prescribe tirzepatide for OSA typically follow a structured 12 to 18 month pathway. Step one is confirming the OSA diagnosis with a sleep study and confirming obesity (BMI ≥30 or ≥27 with comorbidities). Step two is medical screening for thyroid history, gallbladder, pancreatitis risk, diabetic retinopathy, and reproductive plans. Step three is initiating low-dose tirzepatide with weekly self-injection at home and monthly clinic check-ins for the first 3 months.

Step four, around month 6, is a follow-up sleep study to measure interim AHI improvement and decide whether existing devices (CPAP or MAD) can be safely titrated down. Many EU clinics encourage continuing CPAP through the first 6 to 12 months even as weight drops, because removing CPAP too early can cause symptom rebound. Step five, around month 12, is a final sleep study to determine durable AHI status and personalise the long-term plan. Some patients can reduce CPAP pressure substantially or discontinue it; others remain on lower-pressure CPAP.

What to expect financially

Plan for €280 to €340 monthly out of pocket in most EU markets at maintenance dose. National reimbursement is patchy: Germany has the broadest GKV coverage for diagnosed obesity with comorbidities, France HAS-evaluated coverage is limited, the Netherlands and Italy run partial pathways, and the UK NHS funds tightly through specialist obesity services. Some private insurance plans (PKV in Germany, supplementary Mutuelle in France) cover part of the cost.

What to use during the months tirzepatide takes to work

Even at maximum effect, tirzepatide takes 3 to 6 months for OSA-relevant weight loss. During that bridging period, EU patients with diagnosed OSA usually continue or start CPAP if appropriate, or add a mandibular advancement device. For nasal-collapse snoring, the €39 Back2Sleep starter kit is the cheapest CE-certified medical device available without prescription in Europe, with same-day shipping. For primary snoring driven by back-sleeping, positional therapy works the first night.

If you are unsure whether weight or nasal anatomy is driving your snoring, the sleep risk screening can help frame the conversation with your GP. A diagnosed sleep study remains the standard before starting any chronic OSA therapy. For perspective on long-term OSA management strategy, see sleep apnea and diet.

Frequently asked questions

Frequently Asked Questions